Biotech Values

[ghmm]

AERI vs. ITEK

I don't have a big position in ITEK but I am long. I don't see it as an either or especially at this stage of the game. If ITEK's current Phase 3 is successful they still need a 2nd and a long term safety study so AERI is certainly much further along. Also ITEK just started their Phase 2 dose ranging study combining with Latanoprost so it'll be a while before they get to a registration study. To me the valuation was cheap when I got in (after the bio collapse early this year) and saw opportunity for several glaucoma drugs (VRX has one too that had a setback recently). ITEK also said they would do some work with Trabodenoson on eye diseases. I thought we would have some data this year but I would guess it likely isn't going to happen till next year since the company hasn't mentioned it in a while.